KCAS expands ligand binding assay team

Dass joins Masood Khan, senior director of immunoanalytical science and technology at the Shawnee, Kansas-based firm. He will assist with the development of GLP-compliant and non-GLP assays for the conduct of large molecule bioanalytical studies, including PK/TK analysis, immunogenicity evaluation and biomarker quantification.

KCAS uses state-of-the-art immunoanalytical technologies to support large molecule bioanalysis for preclinical and clinical studies (Phase I - IV), as well as rapid bioanalysis for biomarker screening pilot projects.

‘We are very fortunate to have both Dr Khan and Dr Dass at KCAS,’ said president and scientific director Dari Dadgar.

‘Their combined knowledge and skill in working with large molecules, specifically LBA services, has positively impacted our capabilities and we look forward to propelled growth and expansion in the future.’

KCAS has recently purchased Meso Scale Discovery’s Sector Imager 6000, an electrochemiluminescence (ECL) detection technology, which will enable the company to offer immunogenicity assays with better drug tolerance and multi-plex panels for biomarker assays.